{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:12:39Z","timestamp":1771632759544,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40262-020-00944-5","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T02:03:18Z","timestamp":1601517798000},"page":"329-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxim","family":"Kuzin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Paulzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekkehard","family":"Haen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"issue":"9","key":"944_CR1","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789\u201396.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"944_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/acps.13111","volume":"141","author":"JM Rubio","year":"2020","unstructured":"Rubio JM, Kane JM. How and when to use clozapine. Acta Psychiatr Scand. 2020;141(3):178\u201389.","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"944_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000507638","volume":"89","author":"J de Leon","year":"2020","unstructured":"de Leon J, Ruan CJ, Schoretsanitis G, De Las CC. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom. 2020;89(4):200\u201314.","journal-title":"Psychother Psychosom"},{"issue":"1","key":"944_CR4","first-page":"11","volume":"48","author":"FA Mustafa","year":"2015","unstructured":"Mustafa FA, Burke JG, Abukmeil SS, Scanlon JJ, Cox M. \"Schizophrenia past clozapine\": reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing. Pharmacopsychiatry. 2015;48(1):11\u20134.","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"944_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/00042560-200112150-00006","volume":"28","author":"A Ammassari","year":"2001","unstructured":"Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28(5):445\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"944_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jpsychires.2012.05.001","volume":"46","author":"O Caseiro","year":"2012","unstructured":"Caseiro O, Perez-Iglesias R, Mata I, Martinez-Garcia O, Pelayo-Teran JM, Tabares-Seisdedos R, et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res. 2012;46(8):1099\u2013105.","journal-title":"J Psychiatr Res"},{"issue":"3","key":"944_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/JCP.0000000000001198","volume":"40","author":"WH Man","year":"2020","unstructured":"Man WH, Wilting I, Souverein P, Meyboom R, Egberts T, Heerdink ER. Reporting patterns of sialorrhea comparing users of clozapine to users of other antipsychotics: a disproportionality analysis using VigiBase. J Clin Psychopharmacol. 2020;40(3):283\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"944_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/2045125316641019","volume":"6","author":"S Maher","year":"2016","unstructured":"Maher S, Cunningham A, O'Callaghan N, Byrne F, Mc Donald C, McInerney S, et al. Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life. Ther Adv Psychopharmacol. 2016;6(3):178\u201384.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"2","key":"944_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/schbul\/17.2.247","volume":"17","author":"A Safferman","year":"1991","unstructured":"Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull. 1991;17(2):247\u201361.","journal-title":"Schizophr Bull"},{"issue":"3","key":"944_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40263-019-00612-8","volume":"33","author":"SY Chen","year":"2019","unstructured":"Chen SY, Ravindran G, Zhang Q, Kisely S, Siskind D. Treatment strategies for clozapine-induced sialorrhea: a systematic review and meta-analysis. CNS Drugs. 2019;33(3):225\u201338.","journal-title":"CNS Drugs"},{"issue":"3","key":"944_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00213-005-0248-4","volume":"185","author":"SK Praharaj","year":"2006","unstructured":"Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology. 2006;185(3):265\u201373.","journal-title":"Psychopharmacology"},{"issue":"3","key":"944_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJM199307153290303","volume":"329","author":"JM Alvir","year":"1993","unstructured":"Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162\u20137.","journal-title":"N Engl J Med"},{"issue":"5\u20136","key":"944_CR13","first-page":"20","volume":"10","author":"E Trigoboff","year":"2013","unstructured":"Trigoboff E, Grace J, Szymanski H, Bhullar J, Lee C, Watson T. Sialorrhea and aspiration pneumonia: a case study. Innov Clin Neurosci. 2013;10(5\u20136):20\u20137.","journal-title":"Innov Clin Neurosci"},{"issue":"4","key":"944_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3371\/CSRP.SAFI.061213","volume":"9","author":"RC Saenger","year":"2016","unstructured":"Saenger RC, Finch TH, Francois D. Aspiration pneumonia due to clozapine-induced sialorrhea. Clin Schizophr Relat Psychoses. 2016;9(4):170\u20132.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"6","key":"944_CR15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/00004714-199612000-00013","volume":"16","author":"R Hinkes","year":"1996","unstructured":"Hinkes R, Quesada TV, Currier MB, Gonzalez-Blanco M. Aspiration pneumonia possibly secondary to clozapine-induced sialorrhea. J Clin Psychopharmacol. 1996;16(6):462\u20133.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"944_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/wps.20707","volume":"19","author":"J de Leon","year":"2020","unstructured":"de Leon J, Sanz EJ, Noren GN, De Las CC. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics. World Psychiatry. 2020;19(1):120\u20131.","journal-title":"World Psychiatry"},{"issue":"3","key":"944_CR17","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1016\/0922-4106(94)90047-7","volume":"269","author":"SH Zorn","year":"1994","unstructured":"Zorn SH, Jones SB, Ward KM, Liston DR. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol. 1994;269(3):R1\u20132.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"944_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","volume":"12","author":"G Schoretsanitis","year":"2019","unstructured":"Schoretsanitis G, Kane JM, Ruan CJ, Spina E, Hiemke C, de Leon J. A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Rev Clin Pharmacol. 2019;12(7):603\u201321.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"944_CR19","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1111\/odi.12139","volume":"20","author":"J Ekstrom","year":"2014","unstructured":"Ekstrom J, Godoy T, Loy F, Riva A. Parasympathetic vasoactive intestinal peptide (VIP): a likely contributor to clozapine-induced sialorrhoea. Oral Dis. 2014;20(3):e90\u2013e9696.","journal-title":"Oral Dis"},{"issue":"1\u201302","key":"944_CR20","first-page":"9","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1\u201302):9\u201362.","journal-title":"Pharmacopsychiatry"},{"key":"944_CR21","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0219-16.2016","author":"DA MacLaren","year":"2016","unstructured":"MacLaren DA, Browne RW, Shaw JK, Krishnan Radhakrishnan S, Khare P, Espana RA, et al. Clozapine N-oxide administration produces behavioral effects in Long-Evans rats: implications for designing DREADD experiments. eNeuro. 2016. https:\/\/doi.org\/10.1523\/ENEURO.0219-16.2016.","journal-title":"eNeuro."},{"issue":"7","key":"944_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/ijnp\/pyx019","volume":"20","author":"K Toth","year":"2017","unstructured":"Toth K, Csukly G, Sirok D, Belic A, Kiss A, Hafra E, et al. Potential role of patients' CYP3A-status in clozapine pharmacokinetics. Int J Neuropsychopharmacol. 2017;20(7):529\u201337.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"01","key":"944_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1055\/s-2005-862617","volume":"38","author":"W Bader","year":"2005","unstructured":"Bader W, Melchner D, Nonenmacher T, Hean E. Determination of five commonly used antipsychotics in human serum by high performance-liquid chromatography (HPLC) and electrochemical detection. Pharmacopsychiatry. 2005;38(01):4.","journal-title":"Pharmacopsychiatry"},{"key":"944_CR24","unstructured":"Bader W. Therapeutisches Drug Monitoring bei Antipsychotika: Die Entwicklung der Analytik von Antipsychotika und deren Relevanz bei der Therapieleitung schizophrener Patienten am Beispiel des Arzneistoffes Risperidon. Pentling: Saska; 2009."},{"issue":"3","key":"944_CR25","first-page":"142","volume":"76","author":"L Paul","year":"2009","unstructured":"Paul L, Musshoff F, Aebi B, Auw\u00e4rter V, Kr\u00e4mer T, Peters F, et al. Richtlinie der GTFCh zur Qualit\u00e4tssicherung bei forensisch-toxikologischen Untersuchungen. Toxichem Krimtech. 2009;76(3):142\u201376.","journal-title":"Toxichem Krimtech"},{"key":"944_CR26","unstructured":"US Food and Drug Administration. Guidance for industry on biomedical method validation. 2001. https:\/\/www.fda.gov\/ucm\/groups\/fdagov-public\/@fdagov-drugs-gen\/documents\/document\/ucm070107.pdf. Accessed 23 Jun 2020."},{"key":"944_CR27","unstructured":"ICH Group. Harmonised tripartite guideline, validation of analytical procedures: test and methodology. In: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use; 1996. https:\/\/database.ich.org\/sites\/default\/files\/Q2_R1__Guideline.pdf. Accessed 15 Sep 2020."},{"issue":"2","key":"944_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0006-3223(96)00298-3","volume":"42","author":"O Freudenreich","year":"1997","unstructured":"Freudenreich O, Weiner RD, McEvoy JP. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry. 1997;42(2):132\u20137.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"944_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s002130050028","volume":"148","author":"E Spina","year":"2000","unstructured":"Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia AG, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology. 2000;148(1):83\u20139.","journal-title":"Psychopharmacology"},{"issue":"2","key":"944_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/JCP.0000000000001018","volume":"39","author":"CJ Ruan","year":"2019","unstructured":"Ruan CJ, Zang YN, Wang CY, Cheng YH, Sun C, Spina E, et al. Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review. J Clin Psychopharmacol. 2019;39(2):135\u201344.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"944_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/00004714-199408000-00011","volume":"14","author":"C Hiemke","year":"1994","unstructured":"Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol. 1994;14(4):279\u201381.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"944_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/WNF.0b013e3181e204e0","volume":"33","author":"SK Praharaj","year":"2010","unstructured":"Praharaj SK, Jana AK, Goswami K, Das PR, Goyal N, Sinha VK. Salivary flow rate in patients with schizophrenia on clozapine. Clin Neuropharmacol. 2010;33(4):176\u20138.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"944_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5498\/wjp.v5.i1.35","volume":"5","author":"F Manzella","year":"2015","unstructured":"Manzella F, Maloney SE, Taylor GT. Smoking in schizophrenic patients: a critique of the self-medication hypothesis. World J Psychiatry. 2015;5(1):35\u201346.","journal-title":"World J Psychiatry"},{"issue":"1","key":"944_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/14740338.2020.1698545","volume":"19","author":"KA Costa-Dookhan","year":"2020","unstructured":"Costa-Dookhan KA, Agarwal SM, Chintoh A, Tran VN, Stogios N, Ebdrup BH, et al. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. Expert Opin Drug Saf. 2020;19(1):43\u201357.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00944-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00944-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00944-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T01:37:48Z","timestamp":1633052268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00944-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["944"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00944-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"11 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"John M. Kane has been a consultant and\/or advisor for or has received honoraria from Alkermes, Allergan, LB Pharmaceuticals, H. Lundbeck, Intracellular Therapies, Janssen Pharmaceuticals, Johnson and Johnson, Merck, Minerva, Neurocrine, Newron, Otsuka, Pierre Fabre, Reviva, Roche, Sumitomo Dainippon, Sunovion, Takeda, Teva, and UpToDate and is a shareholder in LB Pharmaceuticals and Vanguard Research Group. Christoph Hiemke has received speaker\u2019s or consultancy fees from the following pharmaceutical companies: Janssen-Cilag and Servier. He is the managing director of the psiac GmbH that provides an internet-based drug\u2013drug interaction program for psychopharmacotherapy. He reports no conflicts of interest with this publication. Ekkehard Haen received speaker\u2019s or consultancy fees from the following pharmaceutical companies: Servier, Novartis, and Janssen-Cilag. He is a managing director of AGATE, a non-profit working group to improve drug safety and efficacy in the treatment of psychiatric diseases. He reports no conflict of interest with this publication. Michael Paulzen received speaker\u2019s fees from Neuraxpharm (Langenfeld, Germany) and Lundbeck. He reports no conflicts of interest with this publication. Maxim Kuzin received travel grants from Sunovion Pharmaceutical (Basel, Switzerland) and Otsuka Pharmaceutical (Glattbrugg, Switzerland). He also received a travel grant, and participated and obtained a grant on the speaker\u2019s board of Lundbeck (Zurich, Switzerland). Schoretsanitis Georgios has no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human subjects\/patients were approved by the local regulatory authority.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"No informed consent was required for this type of research.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The original data set is available from the Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg ().","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Participated in research design: GS, JMK, MK, MP, CH, EH. Performed data analysis: GS, MK. Wrote or contributed to the writing of the manuscript: JMK, MK, GS, MP, CH, EH.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}